BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 31961877)

  • 1. Prevalence and genetic profiles of isoniazid resistance in tuberculosis patients: A multicountry analysis of cross-sectional data.
    Dean AS; Zignol M; Cabibbe AM; Falzon D; Glaziou P; Cirillo DM; Köser CU; Gonzalez-Angulo LY; Tosas-Auget O; Ismail N; Tahseen S; Ama MCG; Skrahina A; Alikhanova N; Kamal SMM; Floyd K
    PLoS Med; 2020 Jan; 17(1):e1003008. PubMed ID: 31961877
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Isoniazid resistance profile and associated levofloxacin and pyrazinamide resistance in rifampicin resistant and sensitive isolates/from pulmonary and extrapulmonary tuberculosis patients in Pakistan: A laboratory based surveillance study 2015-19.
    Tahseen S; Khanzada FM; Rizvi AH; Qadir M; Ghazal A; Baloch AQ; Mustafa T
    PLoS One; 2020; 15(9):e0239328. PubMed ID: 32966321
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Co-resistance to isoniazid and second-line anti-tuberculosis drugs in isoniazid-resistant tuberculosis at a tertiary care hospital in Thailand.
    Prommi A; Wongjarit K; Petsong S; Somsukpiroh U; Faksri K; Kawkitinarong K; Payungporn S; Rotcheewaphan S
    Microbiol Spectr; 2024 Mar; 12(3):e0346223. PubMed ID: 38323824
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Principles of chemotherapy for tuberculosis in national tuberculosis programmes of low- and middle-income countries.
    Chiang CY; Lin CJ
    Indian J Tuberc; 2020 Dec; 67(4S):S16-S22. PubMed ID: 33308663
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High Prevalence of inhA Promoter Mutations among Patients with Drug-Resistant Tuberculosis in KwaZulu-Natal, South Africa.
    Niehaus AJ; Mlisana K; Gandhi NR; Mathema B; Brust JC
    PLoS One; 2015; 10(9):e0135003. PubMed ID: 26332235
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The perceived impact of isoniazid resistance on outcome of first-line rifampicin-throughout regimens is largely due to missed rifampicin resistance.
    Van Deun A; Decroo T; Kya Jai Maug A; Hossain MA; Gumusboga M; Mulders W; Ortuño-Gutiérrez N; Lynen L; de Jong BC; Rieder HL
    PLoS One; 2020; 15(5):e0233500. PubMed ID: 32421749
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Whole genome sequencing of drug resistant Mycobacterium tuberculosis isolates from a high burden tuberculosis region of North West Pakistan.
    Jabbar A; Phelan JE; de Sessions PF; Khan TA; Rahman H; Khan SN; Cantillon DM; Wildner LM; Ali S; Campino S; Waddell SJ; Clark TG
    Sci Rep; 2019 Oct; 9(1):14996. PubMed ID: 31628383
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence of isoniazid resistance-conferring mutations associated with multidrug-resistant tuberculosis in Free State Province, South Africa.
    Pitso L; Potgieter S; Van der Spoel van Dijk A
    S Afr Med J; 2019 Aug; 109(9):659-664. PubMed ID: 31635590
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment outcomes for isoniazid-monoresistant tuberculosis in Peru, 2012-2014.
    Cornejo Garcia JG; Alarcón Guizado VA; Mendoza Ticona A; Alarcon E; Heldal E; Moore DAJ
    PLoS One; 2018; 13(12):e0206658. PubMed ID: 30513085
    [TBL] [Abstract][Full Text] [Related]  

  • 10. API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations.
    API Consensus Expert Committee
    J Assoc Physicians India; 2006 Mar; 54():219-34. PubMed ID: 16800350
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries.
    Espinal MA; Kim SJ; Suarez PG; Kam KM; Khomenko AG; Migliori GB; Baéz J; Kochi A; Dye C; Raviglione MC
    JAMA; 2000 May; 283(19):2537-45. PubMed ID: 10815117
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Occurrence of disputed rpoB mutations among Mycobacterium tuberculosis isolates phenotypically susceptible to rifampicin in a country with a low incidence of multidrug-resistant tuberculosis.
    Al-Mutairi NM; Ahmad S; Mokaddas E; Eldeen HS; Joseph S
    BMC Infect Dis; 2019 Jan; 19(1):3. PubMed ID: 30606116
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalences of levofloxacin resistance and
    Ng KKM; Yip PCW; Leung PKL
    Hong Kong Med J; 2021 Dec; 27(6):421-427. PubMed ID: 34949730
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic significance of novel
    Valafar F; Ramirez-Busby SM; Torres J; Paul LV; Rodwell TC; Victor TC; Rodrigues C; Gler MT; Crudu V; Catanzaro T
    Int J Mycobacteriol; 2015 Mar; 4(Suppl 1):51-52. PubMed ID: 27695670
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Initial resistance to companion drugs should not be considered an exclusion criterion for the shorter multidrug-resistant tuberculosis treatment regimen.
    Lempens P; Decroo T; Aung KJM; Hossain MA; Rigouts L; Meehan CJ; Van Deun A; de Jong BC
    Int J Infect Dis; 2020 Nov; 100():357-365. PubMed ID: 32829049
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular characterization of multidrug-resistant Mycobacterium tuberculosis (MDR-TB) isolates identifies local transmission of infection in Kuwait, a country with a low incidence of TB and MDR-TB.
    Al-Mutairi NM; Ahmad S; Mokaddas EM
    Eur J Med Res; 2019 Dec; 24(1):38. PubMed ID: 31806020
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Profile of drug-resistant-conferring mutations among new and previously treated pulmonary tuberculosis cases from Aligarh region of Northern India.
    Ahmed S; Shukla I; Fatima N; Varshney SK; Shameem M; Tayyaba U
    Int J Mycobacteriol; 2018; 7(4):315-327. PubMed ID: 30531028
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of isoniazid-monoresistant tuberculosis (Hr-TB) in Queensland, Australia: a retrospective case series.
    Wilson M; O'Connor B; Matigian N; Eather G
    Respir Med; 2020 Nov; 173():106163. PubMed ID: 33002798
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evolution of Extensively Drug-Resistant Tuberculosis over Four Decades: Whole Genome Sequencing and Dating Analysis of Mycobacterium tuberculosis Isolates from KwaZulu-Natal.
    Cohen KA; Abeel T; Manson McGuire A; Desjardins CA; Munsamy V; Shea TP; Walker BJ; Bantubani N; Almeida DV; Alvarado L; Chapman SB; Mvelase NR; Duffy EY; Fitzgerald MG; Govender P; Gujja S; Hamilton S; Howarth C; Larimer JD; Maharaj K; Pearson MD; Priest ME; Zeng Q; Padayatchi N; Grosset J; Young SK; Wortman J; Mlisana KP; O'Donnell MR; Birren BW; Bishai WR; Pym AS; Earl AM
    PLoS Med; 2015 Sep; 12(9):e1001880. PubMed ID: 26418737
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Variation and risk factors of drug resistant tuberculosis in sub-Saharan Africa: a systematic review and meta-analysis.
    Lukoye D; Ssengooba W; Musisi K; Kasule GW; Cobelens FG; Joloba M; Gomez GB
    BMC Public Health; 2015 Mar; 15():291. PubMed ID: 25880829
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.